Testing effectiveness (Phase 2)Study completedNCT02588651
What this trial is testing
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Who this might be right for
T-cell LymphomaAngioimmunoblastic T-cell LymphomaHepato-splenic T-cell Lymphoma+3 more
Deepa Jagadeesh 23